High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia

Leukemia

Volumn 27, Issue 9, 2013, Pages 1933-1936

  Grossmann, V ^a   Schnittger, S ^a   Poetzinger, F ^a   Kohlmann, A ^a   Stiel, A ^a   Eder, C ^a   Fasan, A ^a   Kern, W ^a   Haferlach, T ^a   Haferlach, C ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CHROMOSOME BANDING PATTERN; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; INCIDENCE; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84883743040     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.90     Document Type: Letter

References (16)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn, International Agency for Research on Cancer (IARC): Lyon, France, 2008.
2. Cosgrove MS, Patel A. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J 2010; 277: 1832-1842.
3. Bach C, Slany RK. Molecular pathology of mixed-lineage leukemia. Future Oncol 2009; 5: 1271-1281.
4. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278.
5. Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 2011; 25: 557-560.
6. Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013; 27: 82-91.
7. Weisser M, Haferlach C, Haferlach T, Schnittger S. Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases. Cancer Genet Cytogenet 2007; 177: 64-69. (Pubitemid 47211295)
8. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009; 114: 2489-2496.
9. Mrozek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW et al. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood 1997; 90: 4532-4538. (Pubitemid 27508459)
10. Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, De LP, Valsecchi MG et al. Frequencies and prognostic impact of RAS mutations in MLLrearranged acute lymphoblastic leukemia in infants. Haematologica 2013; 98: 937-944.
11. Metzeler KH, Sandhofer N, Hinrichsen T, Zellmeier E, Ksienzyk B, Dufour A et al. Analysis of cooperating genetic events in MLLT3-MLL rearranged acute myeloid leukemia (AML) by targeted next-generation sequencing of 16 leukemia-related genes reveals frequent mutations affecting growth factor signalling pathways and provides evidence for clonal heterogeneity. ASH Abstract 2012; 120: 1379.
12. Andersson AK, Ma J, Wang J, Chen X, Rusch M, Wu G et al. Whole genome sequence analysis of MLL rearranged infant acute lymphoblastic leukemias reveals remarkably few somatic mutations:a report from the St Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project. AACR 103rd Ann Meet 2012 2012; 72: S1.
13. Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern W et al. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 2010; 24: 1065-1069.
14. Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood 2013; 121: 170-177.
15. Haferlach C, Bacher U, Grossmann V, Schindela S, Zenger M, Kohlmann A et al. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases. Genes Chromosomes Cancer 2012; 51: 1079-1085.
16. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde s, Hack R et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101: 837-845. (Pubitemid 36139348)